Effects of multicomponent training on lean and bone mass in postmenopausal and older women: a systematic review
Menopause. 2018 Mar;25(3):346-356. doi:10.1097/GME.0000000000000975 Marín-Cascales E, Alcaraz PE, Ramos-Campo DJ, Rubio-Arias JA.
The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
PLoS One. 2018 Mar 15;13(3):e0193846. doi: 10.1371/journal.pone.0193846. eCollection 2018. PubMed PMID: 29543887; PubMed Central PMCID: PMC5854344. Iseri K, Iyoda M, Watanabe M, Matsumoto K, Sanada D, Inoue T, Tachibana S, Shibata T.
Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
J Bone Miner Metab. 2018 Mar 8. doi: 10.1007/s00774-018-0917-0. [Epub ahead of print] PubMed PMID: 29520506. Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T.
Mediterranean diet, diet quality, and bone mineral content in adolescents: the HELENA study.
Osteoporos Int. 2018 Mar 5. doi: 10.1007/s00198-018-4427-7 Julián C, Huybrechts I, Gracia-Marco L, González-Gil EM, Gutiérrez Á, González-Gross M, Marcos A, Widhalm K, Kafatos A, Vicente-Rodríguez G, Moreno LA.
Cross-talk between primary osteocytes and bone marrow macrophages for osteoclastogenesis upon collagen treatment.
Sci Rep. 2018 Mar 28;8(1):5318. doi: 10.1038/s41598-018-23532-x. Elango J, Sanchez C, de Val JEMS, Henrotin Y, Wang S, Motaung KSCM, Guo R, Wang C, Robinson J, Regenstein JM, Bao B, Wu W.
Osseointegration mechanisms: a proteomic approach.
J Biol Inorg Chem. 2018 May;23(3):459-470. doi: 10.1007/s00775-018-1553-9. Araújo-Gomes N, Romero-Gavilán F, García-Arnáez I, Martínez-Ramos C, Sánchez-Pérez AM, Azkargorta M, Elortza F, de Llano JJM, Gurruchaga M, Goñi I, Suay J. https://www.ncbi.nlm.nih.gov/pubmed/29572572
Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on “Variability of denosumab densitometric response in postmenopausal osteoporosis.
Rheumatol Int. 2018 Jun;38(6):1161-1162. doi: 10.1007/s00296-018-4007-3. Torrente-Segarra V, Roig-Vilaseca D.
Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur.
Osteoporos Int. 2018 Feb;29(2):501-506. doi: 10.1007/s00198-017-4286-7. Epub 2017 Oct 30. Greenspan SL, Vujevich K, Britton C, Herradura A, Gruen G, Tarkin I, Siska P, Hamlin B, Perera S.
Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study.
J Bone Miner Res. 2018 Feb;33(2):298-306. Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Melby TE, Ruff … Leer más
TNFα blockade mediates bone protection in antigen-induced arthritis by reducing osteoclast precursor supply.
Bone. 2018 Feb; 107:56-65 Uster S, Matos Coelho F, Aeberli D, Stein JV, Hofstetter W, Engelhardt R, Seitz M.
